Continue Reading
Full article on Yahoo Finance
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
{# Share Buttons Partial Variables: share_title — text to pre-fill in share dialogs share_url — canonical URL to share (use request.build_absolute_uri in parent) #}Market Intelligence Analysis
AI-Powered
Why This Matters
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Sentiment
Neutral
AI Confidence
94%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's common shares...
Original article published by
Yahoo Finance
on March 28, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.